• Non-Canonical Adipose Thermogenesis via Dlat-Trpv3: Anti-Obe

  2026-05-12

  This study uncovers a novel mechanism by which hyperforin enhances adipose thermogenesis through the Dlat-Trpv3-AMPK pathway, providing an alternative anti-obesity strategy independent of classical β3-adrenergic signaling. The findings demonstrate improved safety and efficacy profiles, with implications for translational obesity research.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Re

  2026-05-12

  Xiao et al. (2024) uncover how 25-hydroxycholesterol (25HC), produced by CH25H, accumulates in tumor-associated macrophages (TAMs) to activate AMPKa and promote immunosuppression. Their findings reveal a lysosome-centered metabolic checkpoint that shapes tumor immunity and highlight CH25H as a target to enhance anti-tumor responses, including in combination with immune checkpoint blockade.

• Benzyl Quinolone Carboxylic Acid: Precision M1 mAChR Modulat

  2026-05-11

  Benzyl Quinolone Carboxylic Acid (BQCA) unlocks robust, selective potentiation of M1 muscarinic acetylcholine receptor signaling, offering reproducible, high-sensitivity workflows for cognitive and Alzheimer’s research. APExBIO’s BQCA stands out for its selectivity, brain penetration, and protocol versatility—empowering researchers to overcome common pitfalls in neuropharmacology studies.

• AM 281: Advancing CB1 Antagonism in Neurotrauma Research

  2026-05-11

  This thought-leadership article dissects the mechanistic role of AM 281, a potent CB1 cannabinoid receptor antagonist, in translational neuropharmacology. Drawing on recent mechanistic studies and real-world assay data, it provides actionable guidance for researchers exploring memory impairment, traumatic brain injury (TBI), and cognitive dysfunction. Strategic insights, protocol recommendations, and a rigorous evidence framework are blended to guide the next generation of cannabinoid signaling investigations.

• Targeting Glutamine Metabolism in HSCs to Alleviate Liver Fi

  2026-05-10

  This article analyzes the recent study revealing that modulation of glutamine metabolism in hepatic stellate cells (HSCs), especially via SIRT4-mediated regulation of glutamate dehydrogenase (GDH), can slow or reverse liver fibrosis. The findings highlight new mechanistic targets and experimental strategies for antifibrotic research.

• CX-5461: RNA Polymerase I Inhibitor for Solid Tumor Research

  2026-05-09

  CX-5461 is redefining cancer research by enabling precise inhibition of Pol I-driven rRNA synthesis, offering a potent approach to study ribosome biogenesis and overcome chemoresistance. Its demonstrated synergy with cisplatin in cervical cancer models highlights advanced use-cases for targeting solid tumor growth and optimizing combination therapies.

• (S)-(+)-Dimethindene maleate for M2 Muscarinic Receptor Stud

  2026-05-08

  (S)-(+)-Dimethindene maleate provides selective antagonism of the M2 muscarinic acetylcholine receptor and H1 histamine receptor, supporting precise interrogation of autonomic and cardiovascular pathways. It is intended for controlled laboratory research, not for diagnostic or clinical use, and requires strict adherence to solubility and storage protocols to maintain integrity.

• Chloroquine (BA1002): Application and Best Practices in Rese

  2026-05-08

  Chloroquine (N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine) is a 4-aminoquinoline compound used as an anti-inflammatory agent for malaria research, as well as for studying autophagy and immune modulation. This product is suited for in vitro and in vivo research applications but requires careful adherence to solubility, dosing, and safety parameters. It is not recommended for clinical or translational studies without validated workflows and monitoring.

• GKT137831: Redefining Redox Modulation for Translational Res

  2026-05-07

  This thought-leadership article explores the mechanistic basis and translational strategy for using GKT137831, a dual NADPH oxidase Nox1/Nox4 inhibitor, to address oxidative stress-driven pathologies. Integrating evidence from recent cell biology advances and preclinical models, it provides guidance for experimental design, benchmarks its advantages against the competitive landscape, and projects future directions for redox-targeted interventions in vascular and fibrotic diseases.

• Clozapine in Schizophrenia Research: Protocols and Innovatio

  2026-05-07

  Explore how Clozapine, an atypical antipsychotic medication, is leveraged to dissect receptor signaling and neuroplasticity in advanced schizophrenia models. This guide delivers actionable protocols, troubleshooting strategies, and the latest insights from neuromodulation research—empowering neuroscientists to design robust, translational experiments.

• Disrupting c-MYC/G9a Axis: Co-Targeting BRD4 and RAC1 in Bre

  2026-05-06

  This study introduces a co-targeting approach inhibiting both BRD4 and RAC1, revealing suppression of breast cancer cell growth and stemness via disruption of the c-MYC-G9a-FTH1 axis and downregulation of HDAC1. The findings highlight a mechanistic link between chromatin modification and oncogenic signaling, providing a rationale for precision epigenetic intervention in heterogeneous breast cancer subtypes.

• Ampicillin Sodium: Precision Benchmarking for Antibacterial

  2026-05-06

  Explore the scientific rigor and precision benchmarking of Ampicillin sodium, a β-lactam antibiotic, in advanced antibacterial activity assays. This article uniquely dissects comparative data, assay optimization, and best practices for translational research.

• AMPK-JAK2/STAT3 Axis Modulates M1 Macrophages in Obesity-Lin

  2026-05-05

  This study elucidates how AMPK downregulation drives M1 macrophage polarization and airway inflammation in obesity-related asthma, revealing the JAK2/STAT3 pathway as a mechanistic link. The findings clarify therapeutic opportunities for targeting metabolic-inflammation crosstalk in severe, steroid-resistant asthma.

• NU7441 (KU-57788): Selective DNA-PK Inhibition for DNA Repai

  2026-05-05

  NU7441 (KU-57788) is a potent, selective ATP-competitive DNA-PK inhibitor, essential for dissecting DNA repair and oncology pathways. It achieves nanomolar inhibition with minimal off-target activity and is widely adopted in cell cycle and cancer research. NU7441 enables precise modulation of DNA damage responses in both in vitro and in vivo models.

• Fludarabine as a DNA Synthesis Inhibitor: Oncology Workflows

  2026-05-04

  Fludarabine stands out as a rigorously validated DNA synthesis inhibitor, enabling precise manipulation of cell cycle arrest and apoptosis in leukemia and multiple myeloma research. Recent breakthroughs show it can also remodel tumor antigenicity, unlocking synergy with immunotherapies. This guide translates the latest experimental findings into actionable workflows, troubleshooting, and advanced use-cases.

16309 records 1/1088 page Next 12345 下5页 Last page